SOURCE: Therapeutics: 101 Inc.

February 07, 2007 10:00 ET

Medical Company, Therapeutics: 101 Inc., Develops a New Institutional Asset for Patients Undergoing Anesthesia and Surgery

BEVERLY HILLS, CA -- (MARKET WIRE) -- February 7, 2007 -- "A valuable tool has been added to the use of the newly developed noninvasive Pressure Right™ adhesive acupressure wristband for maximum effect in preventing postoperative nausea and vomiting (PONV)," said Paul A. Lessler, M.D., Medical Director of Therapeutics: 101 Inc.

A newly designed template is now provided with Pressure Right™ for exact placement on the vital (P6) acupressure point located on the inner wrist for combating (PONV). Pressure Right™ has been found to provide surgical patients with a high level of efficacy in preventing the incidence of (PONV) during the first 24 hours following surgery.

In a recent study of high risk (PONV) patients all the participants of the study were given standard drug therapy preoperatively. Using the Pressure Right™ wristband, Mark Shulman, M.D., Director of Anesthesiology and Pain Medicine at Caritas St. Elizabeth's Medical Center, Boston, MA, showed a much higher response in preventing postoperative nausea and vomiting as compared to those treated with medications alone.

The Pressure Right™ (P6) pressure point template provides an automatic and accurate location of the (P6) point location on a patient's wrist. This facilitates easy and correct application of the device by medical personnel prior to surgical procedures.

Dr. Lessler said, "As a board certified anesthesiologist with over 40 years of teaching and practice experience, I see Pressure Right™ being rapidly adopted by anesthesiologists as an indispensable adjunct to the standard drug therapy in reducing the incidence of postoperative nausea and vomiting to its lowest possible level."

The addition of Pressure Right™ to standard antiemetic therapy has proven to substantially exceed the prolonged benefits of drug therapy alone. Moreover, this adhesive acupressure wristband has no side effects for patients and is a low-cost preventive option, which will translate into cost savings for patients and hospitals.

Contact Information

  • Company Contacts:

    Joseph DiLustro
    CEO & President
    Therapeutics: 101 Inc.
    Tinton Falls, NJ
    (908) 601-8877
    Email Contact

    Paul A. Lessler, M.D., FACA
    Medical Director
    Therapeutics: 101 Inc.
    Beverly Hills, CA
    (949) 887-8800
    Email Contact